Yu, Kyung‐Sang

Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013

Suh, H. Y., Peck, C., Yu, K.-S., & Lee, H. (2016) · Drug Design, Development and Therapy

Statistical Methods in Clinical TrialsMonoclonal and Polyclonal Antibodies Research

Cited by 51

Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl‐tRNA synthetase inhibitor, in healthy subjects

Park, M. Y., Bae, S., Heo, J. A., Park, M., Kim, Y., Han, J., Jang, I., Yu, K., & Oh, J. (2023) · Clinical and Translational Science

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPharmacogenetics and Drug Metabolism

Cited by 15

Effects of meal type on the bioavailability of vutiglabridin, a novel anti-obesity agent, in healthy subjects

Won, H., Yoon, D. Y., Lee, S., Cho, J., Oh, J., Jang, I., Yoo, S., & Yu, K. (2024) · Clinical and Translational Science

Pharmacology and Obesity TreatmentPharmacogenetics and Drug Metabolism

Cited by 3